TransCode Therapeutics, Inc. (RNAZ)
RNAZ moved a median of -0.88% 30 minutes after news, and -1.45% by the close. How RNAZ actually reacts to news — the realized, point-in-time move the market made, measured across 248 labeled events over the last three years with zero look-ahead.
RNAZ’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.82% | 30% | 221 |
| 30-min | -0.88% | 43% | 236 |
| 60-min | -0.99% | 40% | 240 |
| to close | -1.45% | 39% | 247 |
| Middle 50% of RNAZ reactions | -5.02% to +1.91% |
|---|---|
| Median reaction (30-min) | -0.88% |
| Measured reactions | 248 |
Half of all TransCode Therapeutics, Inc. news events land between -5.02% and +1.91% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when RNAZ moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RNAZ's baseline. Nothing else.
Recent RNAZ events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Transcode Therapeutics, For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.63% | |
| Form 8-K Transcode Therapeutics, For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | — | +3.01% | |
| TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up | Press release | PR Newswire | — | +3.01% | |
| TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology | Press release | PR Newswire | +1.08% | -4.32% | |
| Join Today's Live Investor Webinar with TransCode Therapeutics | Press release | ACCESS Newswire | +0.00% | +1.21% | |
| Form 8-K Transcode Therapeutics, For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| TransCode Therapeutics Announces Leadership Transition | Press release | PR Newswire | -3.53% | -0.59% | |
| Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer | Press release | ACCESS Newswire | -3.74% | -5.07% | |
| TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis | Press release | PR Newswire | -9.52% | +0.00% | |
| Form 10-Q Transcode Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.49% | -5.95% | |
| Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV | Press release | ACCESS Newswire | +4.50% | -1.00% | |
| Form 8-K Transcode Therapeutics, For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +7.76% | +1.60% | |
| Form 8-K Transcode Therapeutics, For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | — | -2.44% | |
| Form 8-K Transcode Therapeutics, For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.58% | |
| Form DEFA14A Transcode Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +0.58% | |
| Form 8-K Transcode Therapeutics, For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | -1.74% | -12.70% | |
| Form 8-K Transcode Therapeutics, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | — | -9.44% | |
| TransCode Therapeutics to Host R&D Webcast on June 18, 2026 | Press release | PR Newswire | +0.00% | -6.26% | |
| Form 8-K Transcode Therapeutics, For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -0.82% | +18.59% | |
| TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer | Press release | PR Newswire | -0.82% | +18.59% | |
| Form ARS Transcode Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.82% | +18.59% | |
| Form DEF 14A Transcode Therapeutics, For: Jul 02 | SEC filing · Form DEF | SEC EDGAR | -0.82% | +18.59% | |
| Form 8-K Transcode Therapeutics, For: May 29 | SEC filing · Form 8-K | SEC EDGAR | +4.87% | +5.95% | |
| TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer | Press release | PR Newswire | +0.00% | -2.12% | |
| Form 8-K/A Transcode Therapeutics, For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -3.68% | -0.74% | |
| Form DEFA14A Transcode Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -3.68% | -0.74% | |
| Form 8-K Transcode Therapeutics, For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -3.68% | -0.74% | |
| Form EFFECT Transcode Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | — | -1.45% | |
| Form 10-Q Transcode Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | -6.51% | |
| Form PRE 14A Transcode Therapeutics, For: May 08 | SEC filing · Form PRE | SEC EDGAR | -1.54% | -1.69% | |
| Form S-1 Transcode Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | — | -6.79% | |
| Form 10-K/A Transcode Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | -4.69% | |
| Form S-3 Transcode Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | — | -4.69% | |
| TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University | Press release | PR Newswire | — | — | |
| Form 10-K Transcode Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | -2.03% | |
| Form 8-K Transcode Therapeutics, For: Apr 06 | SEC filing · Form 8-K | SEC EDGAR | — | -3.97% | |
| Form DEFA14A Transcode Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | — | -3.97% | |
| TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 | Press release | PR Newswire | — | -3.97% | |
| Form NT 10-K Transcode Therapeutics, For: Dec 31 | SEC filing · Form NT | SEC EDGAR | — | +1.40% | |
| Form 8-K Transcode Therapeutics, For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | — | -1.21% | |
| Form DEFA14A Transcode Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | — | -1.21% | |
| TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer | Press release | PR Newswire | +2.09% | +2.09% | |
| Form 8-K Transcode Therapeutics, For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | -1.91% | -0.21% | |
| TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development | Press release | PR Newswire | -1.91% | -0.21% | |
| Form 8-K Transcode Therapeutics, For: Feb 05 | SEC filing · Form 8-K | SEC EDGAR | -5.10% | -15.29% | |
| TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 | Press release | PR Newswire | -5.10% | -15.29% | |
| Form 8-K Transcode Therapeutics, For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | +4.40% | +4.54% | |
| TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma | Press release | PR Newswire | +4.40% | +4.54% | |
| Form 8-K/A Transcode Therapeutics, For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | +2.13% | -0.93% | |
| Form DEFA14A Transcode Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +2.13% | -0.93% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RNAZ section they belong to.
Where else RNAZ is measured.
RNAZ earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is TransCode Therapeutics, Inc.'s median reaction calculated?
Every labeled RNAZ news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 248 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of RNAZ's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RNAZ's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.